(Q34290462)

1 August 2017

title

Hodgkin's lymphoma in adults (English)

1 reference

1 August 2017

2

David Linch

1 reference

1 August 2017

William Townsend

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

25 July 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

380

1 reference

1 August 2017

issue

9844

1 reference

1 August 2017

page(s)

836-847

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

1 August 2017

1 reference

7 January 2021

Incidence patterns and outcomes for hodgkin lymphoma patients in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Incidence of Hodgkin's disease in Nordic countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

The molecular pathogenesis of Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

The biology of Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

The value of staging bone marrow trephine biopsy in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 t

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Involved-field radiotherapy for advanced Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle L

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

How I treat relapsed and refractory Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Use of chemotherapy during human pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Hodgkin lymphoma among patients infected with HIV in post-HAART era.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

State-of-the-art Issues in Hodgkin’s Lymphoma Survivorship

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Management of fertility in patients treated for Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adult

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960035-X

7 January 2021

10.1016/S0140-6736(12)60035-X

Identifiers

DOI

1 reference

1 August 2017

1 reference